No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials
Abstract Background Secukinumab is an interleukin (IL)-17 inhibitor approved to treat patients with axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Treatment recommendations highlight the importance of individualized treatment of patients with axSpA...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2026-04-01
|
| coleção: | Arthritis Research & Therapy |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s13075-026-03804-y |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|